Medical cannabis in Europe is not covered by a harmonised regulatory framework. However, Arriello director of drug safety, Peter Kohut, argues that this should not deter pharma companies from pursuing this increasingly attractive opportunity.

Major global cannabis exporters cannot tap into a common regulatory pathway to European markets. Cannabis is a massive opportunity, but marketing cannabis products in the diverse European market is a complex challenge, writes Arriello Director of Drug Safety Peter Kohut.

Medical cannabis is a growing market in Europe – but there is a lack of the usual regulatory framework intended to harmonise marketing of medicines and keep them safe. Arriello Director of Drug Safety Peter Kohut provides a guide to marketing cannabis products in the diverse European market.

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.